论文部分内容阅读
目的观察肺表面活性物质预防新生儿呼吸窘迫综合征(NRDS)的疗效。方法将76例新生儿呼吸窘迫综合征患儿按治疗方式不同随机分为对照组和观察组各38例,对照组给予吸痰、吸氧、预防出血、抗感染及机械通气等常规治疗,观察组在此基础上给予肺表面活性物质固尔苏治疗,观察两组治疗后疗效。结果两组NRDS的发生率分别为36.84%和13.16%,充血性心力衰竭发生率分别为39.47%和10.53%,观察组显著低于对照组(P<0.05);治疗6h后,观察组PaO2、PCO2及pH改善明显优于对照组,差异均有统计学意义(P<0.05)。结论肺表面肺表面活性物质可有效预防NRDS的发生,并可减少并发症的发生率,值得推广应用。
Objective To observe the efficacy of pulmonary surfactant in the prevention of neonatal respiratory distress syndrome (NRDS). Methods A total of 76 neonates with respiratory distress syndrome were randomly divided into control group and observation group according to the different treatment methods. The control group was given routine treatment such as suctioning, oxygen, prevention of bleeding, anti-infection and mechanical ventilation. On this basis, the group given the curettage of pulmonary surfactant, to observe the curative effect of the two groups after treatment. Results The incidences of NRDS in the two groups were 36.84% and 13.16% respectively, and the incidences of congestive heart failure were 39.47% and 10.53% in the observation group and significantly lower than those in the control group (P <0.05) PCO2 and pH improved significantly better than the control group, the difference was statistically significant (P <0.05). Conclusion Pulmonary surfactant can effectively prevent the occurrence of NRDS and reduce the incidence of complications, which is worth popularizing.